Literature DB >> 17067639

Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Jessica P Ryman-Rasmussen1, Adam Griffith, Scott Oloff, Nagarajan Vaidehi, Justin T Brown, William A Goddard, Richard B Mailman.   

Abstract

Recently, we demonstrated that D(1) agonists can cause functionally selective effects when the endpoints of receptor internalization and adenylate cyclase activation are compared. The present study was designed to probe the phenomenon of functional selectivity at the D(1) receptor further by testing the hypothesis that structurally dissimilar agonists with efficacies at these endpoints that equal or exceed those of dopamine would differ in ability to influence receptor fate after internalization, a functional endpoint largely unexplored for the D(1) receptor. We selected two novel agonists of therapeutic interest that meet these criteria (the isochroman A-77636, and the isoquinoline dinapsoline), and compared the fates of the D(1) receptor after internalization in response to these two compounds with that of dopamine. We found that dopamine caused the receptor to be rapidly recycled to the cell surface within 1h of removal. Conversely, A-77636 caused the receptor to be retained intracellularly up to 48 h after agonist removal. Most surprisingly, the D(1) receptor recovered to the cell surface 48 h after removal of dinapsoline. Taken together, these data indicate that these agonists target the D(1) receptor to different intracellular trafficking pathways, demonstrating that the phenomenon of functional selectivity at the D(1) receptor is operative for cellular events that are temporally downstream of immediate receptor activation. We hypothesize that these differential effects result from interactions of the synthetic ligands with aspects of the D(1) receptor that are distal from the ligand binding domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067639      PMCID: PMC1855220          DOI: 10.1016/j.neuropharm.2006.08.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  31 in total

1.  Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases.

Authors:  M Tiberi; S R Nash; L Bertrand; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

2.  Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.

Authors:  C W Lin; B R Bianchi; T R Miller; M A Stashko; S S Wang; P Curzon; L Bednarz; K E Asin; D R Britton
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

3.  Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes.

Authors:  J Zhang; L S Barak; P H Anborgh; S A Laporte; M G Caron; S S Ferguson
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

4.  Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression.

Authors:  K E Asin; D Wirtshafter
Journal:  Eur J Pharmacol       Date:  1993-04-22       Impact factor: 4.432

5.  G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase.

Authors:  D Hervé; M Lévi-Strauss; I Marey-Semper; C Verney; J P Tassin; J Glowinski; J A Girault
Journal:  J Neurosci       Date:  1993-05       Impact factor: 6.167

6.  9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.

Authors:  D Ghosh; S E Snyder; V J Watts; R B Mailman; D E Nichols
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

7.  Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency.

Authors:  M M Lewis; V J Watts; C P Lawler; D E Nichols; R B Mailman
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

8.  Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.

Authors:  D M Mottola; S Laiter; V J Watts; A Tropsha; S D Wyrick; D E Nichols; R B Mailman
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

9.  A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.

Authors:  J W Kebabian; D R Britton; M P DeNinno; R Perner; L Smith; P Jenner; R Schoenleber; M Williams
Journal:  Eur J Pharmacol       Date:  1992-12-15       Impact factor: 4.432

10.  Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes.

Authors:  R G Vickery; M von Zastrow
Journal:  J Cell Biol       Date:  1999-01-11       Impact factor: 10.539

View more
  21 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

3.  D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Authors:  Yang Yang; Sang-Min Lee; Fumiaki Imamura; Krishne Gowda; Shantu Amin; Richard B Mailman
Journal:  Mol Psychiatry       Date:  2018-12-07       Impact factor: 15.992

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 5.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact.

Authors:  Terry Kenakin; Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2012-02-15       Impact factor: 84.694

Review 6.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

Review 7.  Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Authors:  Srikrishnan Mallipeddi; David R Janero; Nikolai Zvonok; Alexandros Makriyannis
Journal:  Biochem Pharmacol       Date:  2016-11-24       Impact factor: 5.858

8.  Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.

Authors:  Guang Bai; Iris Cheung; Hennady P Shulha; Joana E Coelho; Ping Li; Xianjun Dong; Mira Jakovcevski; Yumei Wang; Anastasia Grigorenko; Yan Jiang; Andrew Hoss; Krupal Patel; Ming Zheng; Evgeny Rogaev; Richard H Myers; Zhiping Weng; Schahram Akbarian; Jiang-Fan Chen
Journal:  Hum Mol Genet       Date:  2014-12-05       Impact factor: 6.150

Review 9.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

10.  Differential activation and trafficking of micro-opioid receptors in brain slices.

Authors:  Seksiri Arttamangkul; Nidia Quillinan; Malcolm J Low; Mark von Zastrow; John Pintar; John T Williams
Journal:  Mol Pharmacol       Date:  2008-07-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.